China's Akeso rises on progress of cervical cancer drug

Akeso

23/11/2023 04:57

** Shares of China's biological products developer Akeso Inc
 9926.HK  rise 5.1% to HK$48.75, on course for the biggest
one-day pct rise since Nov 6, if gains hold
    ** Guangdong-based co says Phase III clinical trial of
cadonilimab, AK104-303, reached Progression-Free-Survival
primary endpoint at interim analysis for first line treatment of
cervical cancer and demonstrates significant survival benefits
for all comers
    ** Says the trend of overall survival (OS) improvement was
observed and the trial will continue as planned to confirm OS
benefit 
    ** Hong Kong's healthcare index  .HSCIH  gains 0.04% while
Hang Seng Composite Index  .HSCI  down 0.4%
    ** Stock up 11.6% YTD 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))